As previously reported, Baird raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $95 from $88 and keeps an Outperform rating on the shares after Mirum’s preliminary Q4 and FY25 sales came in ahead of expectations, including the upper end of their guidance. Management apparently sees durability in the performance with guidance for continued strong growth in 2026, adds the analyst, who is raising the firm’s price target citing the commercial strength.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $95 from $88 at Baird
- Mirum Pharmaceuticals sees FY26 revenue $630M-$650M, consensus $595.94M
- Mirum Pharmaceuticals reports preliminary Q4 revenue $149M, consensus $135.72M
- Mirum Pharmaceuticals Announces Strong 2025 Sales and 2026 Outlook
- Mirum Files Patent Suits to Block Livmarli Generics